Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1397304

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1397304

Nasal Allergy Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

PUBLISHED:
PAGES: 250 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PPT Slides/PDF & Excel (Enterprise License)
USD 4995

Add to Cart

Description

Table of Contents

The global nasal allergy treatment market is poised to exhibit substantial growth, with a Compound Annual Growth Rate (CAGR) of 5% expected from 2024 to 2031. The market was valued at approximately US$ 14.9 billion in 2024.

Overview of Nasal Allergy (Allergic Rhinitis)

Nasal allergy, or allergic rhinitis (AR), is a non-infectious inflammatory condition of the nasal mucosa triggered by exposure to inhaled allergens. It involves immune responses mediated by IgE, various immune cells, and cytokines. The prevalence of AR continues to rise globally, especially in low- and middle-income countries.

Standard of Care for Nasal Allergy Treatment

The standard of care for AR involves a treatment plan that considers the condition's severity, coexisting allergy conditions, and patient preferences. Treatment typically begins with allergen avoidance strategies, such as minimizing exposure to relevant allergens, maintaining indoor humidity below 40%, and using high-efficiency particulate air (HEPA) filters to remove allergens from indoor air.

If allergen avoidance strategies prove ineffective, pharmacological options are considered, starting with antihistamines and intranasal glucocorticoids as initial symptomatic treatments.

Factors Driving Demand for Nasal Allergy Treatment

Several factors are propelling the demand for nasal allergy treatment, including:

  • 1. Increasing Awareness: Rising global awareness of allergic responses is driving demand for treatment options.
  • 2. Pharmacological Advances: Drug manufacturers are expanding treatment options by offering a variety of drug administration modalities, such as high-quality medications and nasal sprays.
  • 3. Digital Technology: The World Health Organization (WHO) emphasizes the role of digital technology in advancing healthcare systems and achieving health-related Sustainable Development Goals. Mobile technology, electronic diaries, personalized feedback, and patient-specific education contribute to improved treatment adherence and patient care.

Challenges and Restrictions Affecting Nasal Allergy Treatment

Despite significant advances in treatment options, challenges and restrictions still exist, including:

  • 1. Allergy Immunotherapy Limitations: Allergy immunotherapy, considered the most effective etiological treatment for AR, has drawbacks, including high cost, systemic side effects, prolonged treatment duration, and a lack of biomarkers to predict treatment outcomes.
  • 2. Adherence Issues: Many patients have difficulty adhering to prescribed medications, even though most respond well to pharmacotherapy.
  • 3. Recurrence after Treatment: Some treatment approaches, like placental extract submucosal injections, may lead to symptom alleviation during treatment but could result in symptom recurrence after treatment ends.

Market Outlook for the United States

The United States has established care paradigms that provide patients with access to various reimbursement programs for nasal allergy treatment through Medicare and Medicaid Services. Increased patient education on nasal allergy symptoms and management has further fueled market growth in the country.

China's Lucrative Market for Nasal Allergy Treatment

China has witnessed a significant increase in the incidence of AR in recent years, impacting the general population. This trend underscores the need for a better understanding of AR's prevalence, attributes, sensitivity patterns, and associated risk factors to enhance treatment and preventive measures.

Outlook of the United Kingdom Market

The United Kingdom, with a high incidence of allergic rhinitis due to a significant population of smokers, has a growing demand for nasal allergy treatment.

Competitive Landscape

The nasal allergy treatment market is characterized by fragmentation, with key players focusing on research and development to introduce novel products. Market participants also engage in strategic mergers and collaborations to expand their product portfolios and enhance pipeline products.

Key Companies Profiled

  • Merck & Co.
  • Boehringer Ingelheim
  • AstraZeneca
  • GlaxoSmithKline PLC
  • Sanofi S.A.
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.
  • Alcon (Novartis AG)
  • Stallergenes Greer
  • Allergy Therapeutics
  • ALK-Abello A/S
  • Hanmi Pharmaceutical
  • Immunotek
  • Regeneron Pharmaceuticals
  • Abdi Ibrahim Pharmaceuticals
  • Glenmark

Market Segmentation

By Treatment:

  • Immunotherapy
  • Antihistamines
  • Decongestants
  • Corticosteroids
  • Others

By Disease:

  • Seasonal Allergic Rhinitis
  • Perennial Allergic Rhinitis
  • Occupational Allergic Rhinitis

By Route of Administration:

  • Oral
  • Nasal
  • Intraocular
  • Intravenous

By Distribution Channel:

  • Retail Pharmacies
  • Hospital Pharmacies
  • e-Commerce

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa (MEA)
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global Nasal Allergy Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Nasal Allergy Treatment Market Outlook, 2018 - 2031

  • 3.1. Global Nasal Allergy Treatment Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Immunotherapy
      • 3.1.1.2. Antihistamines
      • 3.1.1.3. Decongestants
      • 3.1.1.4. Corticosteroids
      • 3.1.1.5. Others
  • 3.2. Global Nasal Allergy Treatment Market Outlook, by Disease, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Seasonal Allergic Rhinitis
      • 3.2.1.2. Perennial Allergic Rhinitis
      • 3.2.1.3. Occupational Allergic Rhinitis
  • 3.3. Global Nasal Allergy Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Oral
      • 3.3.1.2. Nasal
      • 3.3.1.3. Intraocular
      • 3.3.1.4. Intravenous
  • 3.4. Global Nasal Allergy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. Retail Pharmacies
      • 3.4.1.2. Hospital Pharmacies
      • 3.4.1.3. E - Commerce
  • 3.5. Global Nasal Allergy Treatment Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.5.1. Key Highlights
      • 3.5.1.1. North America
      • 3.5.1.2. Europe
      • 3.5.1.3. Asia Pacific
      • 3.5.1.4. Latin America
      • 3.5.1.5. Middle East & Africa

4. North America Nasal Allergy Treatment Market Outlook, 2018 - 2031

  • 4.1. North America Nasal Allergy Treatment Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Immunotherapy
      • 4.1.1.2. Antihistamines
      • 4.1.1.3. Decongestants
      • 4.1.1.4. Corticosteroids
      • 4.1.1.5. Others
  • 4.2. North America Nasal Allergy Treatment Market Outlook, by Disease, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Seasonal Allergic Rhinitis
      • 4.2.1.2. Perennial Allergic Rhinitis
      • 4.2.1.3. Occupational Allergic Rhinitis
  • 4.3. North America Nasal Allergy Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Oral
      • 4.3.1.2. Nasal
      • 4.3.1.3. Intraocular
      • 4.3.1.4. Intravenous
  • 4.4. North America Nasal Allergy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. Retail Pharmacies
      • 4.4.1.2. Hospital Pharmacies
      • 4.4.1.3. E - Commerce
  • 4.5. North America Nasal Allergy Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.5.1. Key Highlights
      • 4.5.1.1. U.S. Nasal Allergy Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 4.5.1.2. U.S. Nasal Allergy Treatment Market Indication, Value (US$ Bn), 2018 - 2031
      • 4.5.1.3. U.S. Nasal Allergy Treatment Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 4.5.1.4. U.S. Nasal Allergy Treatment Market End User, Value (US$ Bn), 2018 - 2031
      • 4.5.1.5. Canada Nasal Allergy Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 4.5.1.6. Canada Nasal Allergy Treatment Market Indication, Value (US$ Bn), 2018 - 2031
      • 4.5.1.7. Canada Nasal Allergy Treatment Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 4.5.1.8. Canada Nasal Allergy Treatment Market End User, Value (US$ Bn), 2018 - 2031
    • 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Nasal Allergy Treatment Market Outlook, 2018 - 2031

  • 5.1. Europe Nasal Allergy Treatment Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Immunotherapy
      • 5.1.1.2. Antihistamines
      • 5.1.1.3. Decongestants
      • 5.1.1.4. Corticosteroids
      • 5.1.1.5. Others
  • 5.2. Europe Nasal Allergy Treatment Market Outlook, by Disease, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Seasonal Allergic Rhinitis
      • 5.2.1.2. Perennial Allergic Rhinitis
      • 5.2.1.3. Occupational Allergic Rhinitis
  • 5.3. Europe Nasal Allergy Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Oral
      • 5.3.1.2. Nasal
      • 5.3.1.3. Intraocular
      • 5.3.1.4. Intravenous
  • 5.4. Europe Nasal Allergy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Retail Pharmacies
      • 5.4.1.2. Hospital Pharmacies
      • 5.4.1.3. E - Commerce
  • 5.5. Europe Nasal Allergy Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.5.1. Key Highlights
      • 5.5.1.1. Germany Nasal Allergy Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.5.1.2. Germany Nasal Allergy Treatment Market Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.3. Germany Nasal Allergy Treatment Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.4. Germany Nasal Allergy Treatment Market End User, Value (US$ Bn), 2018 - 2031
      • 5.5.1.5. U.K. Nasal Allergy Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.5.1.6. U.K. Nasal Allergy Treatment Market Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.7. U.K. Nasal Allergy Treatment Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.8. U.K. Nasal Allergy Treatment Market End User, Value (US$ Bn), 2018 - 2031
      • 5.5.1.9. France Nasal Allergy Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.5.1.10. France Nasal Allergy Treatment Market Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.11. France Nasal Allergy Treatment Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.12. France Nasal Allergy Treatment Market End User, Value (US$ Bn), 2018 - 2031
      • 5.5.1.13. Italy Nasal Allergy Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.5.1.14. Italy Nasal Allergy Treatment Market Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.15. Italy Nasal Allergy Treatment Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.16. Italy Nasal Allergy Treatment Market End User, Value (US$ Bn), 2018 - 2031
      • 5.5.1.17. Turkey Nasal Allergy Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.5.1.18. Turkey Nasal Allergy Treatment Market Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.19. Turkey Nasal Allergy Treatment Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.20. Turkey Nasal Allergy Treatment Market End User, Value (US$ Bn), 2018 - 2031
      • 5.5.1.21. Russia Nasal Allergy Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.5.1.22. Russia Nasal Allergy Treatment Market Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.23. Russia Nasal Allergy Treatment Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.24. Russia Nasal Allergy Treatment Market End User, Value (US$ Bn), 2018 - 2031
      • 5.5.1.25. Rest of Europe Nasal Allergy Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.5.1.26. Rest of Europe Nasal Allergy Treatment Market Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.27. Rest of Europe Nasal Allergy Treatment Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.28. Rest of Europe Nasal Allergy Treatment Market End User, Value (US$ Bn), 2018 - 2031
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Nasal Allergy Treatment Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Nasal Allergy Treatment Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Immunotherapy
      • 6.1.1.2. Antihistamines
      • 6.1.1.3. Decongestants
      • 6.1.1.4. Corticosteroids
      • 6.1.1.5. Others
  • 6.2. Asia Pacific Nasal Allergy Treatment Market Outlook, by Disease, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Seasonal Allergic Rhinitis
      • 6.2.1.2. Perennial Allergic Rhinitis
      • 6.2.1.3. Occupational Allergic Rhinitis
  • 6.3. Asia Pacific Nasal Allergy Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Oral
      • 6.3.1.2. Nasal
      • 6.3.1.3. Intraocular
      • 6.3.1.4. Intravenous
  • 6.4. Asia Pacific Nasal Allergy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. Retail Pharmacies
      • 6.4.1.2. Hospital Pharmacies
      • 6.4.1.3. E - Commerce
  • 6.5. Asia Pacific Nasal Allergy Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.5.1. Key Highlights
      • 6.5.1.1. China Nasal Allergy Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 6.5.1.2. China Nasal Allergy Treatment Market Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.3. China Nasal Allergy Treatment Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.4. China Nasal Allergy Treatment Market End User, Value (US$ Bn), 2018 - 2031
      • 6.5.1.5. Japan Nasal Allergy Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 6.5.1.6. Japan Nasal Allergy Treatment Market Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.7. Japan Nasal Allergy Treatment Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.8. Japan Nasal Allergy Treatment Market End User, Value (US$ Bn), 2018 - 2031
      • 6.5.1.9. South Korea Nasal Allergy Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 6.5.1.10. South Korea Nasal Allergy Treatment Market Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.11. South Korea Nasal Allergy Treatment Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.12. South Korea Nasal Allergy Treatment Market End User, Value (US$ Bn), 2018 - 2031
      • 6.5.1.13. India Nasal Allergy Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 6.5.1.14. India Nasal Allergy Treatment Market Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.15. India Nasal Allergy Treatment Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.16. India Nasal Allergy Treatment Market End User, Value (US$ Bn), 2018 - 2031
      • 6.5.1.17. Southeast Asia Nasal Allergy Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 6.5.1.18. Southeast Asia Nasal Allergy Treatment Market Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.19. Southeast Asia Nasal Allergy Treatment Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.20. Southeast Asia Nasal Allergy Treatment Market End User, Value (US$ Bn), 2018 - 2031
      • 6.5.1.21. Rest of Asia Pacific Nasal Allergy Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 6.5.1.22. Rest of Asia Pacific Nasal Allergy Treatment Market Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.23. Rest of Asia Pacific Nasal Allergy Treatment Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.24. Rest of Asia Pacific Nasal Allergy Treatment Market End User, Value (US$ Bn), 2018 - 2031
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Nasal Allergy Treatment Market Outlook, 2018 - 2031

  • 7.1. Latin America Nasal Allergy Treatment Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Immunotherapy
      • 7.1.1.2. Antihistamines
      • 7.1.1.3. Decongestants
      • 7.1.1.4. Corticosteroids
      • 7.1.1.5. Others
  • 7.2. Latin America Nasal Allergy Treatment Market Outlook, by Disease, Value (US$ Bn), 2018 - 2031
      • 7.2.1.1. Seasonal Allergic Rhinitis
      • 7.2.1.2. Perennial Allergic Rhinitis
      • 7.2.1.3. Occupational Allergic Rhinitis
  • 7.3. Latin America Nasal Allergy Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Oral
      • 7.3.1.2. Nasal
      • 7.3.1.3. Intraocular
      • 7.3.1.4. Intravenous
  • 7.4. Latin America Nasal Allergy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Retail Pharmacies
      • 7.4.1.2. Hospital Pharmacies
      • 7.4.1.3. E - Commerce
  • 7.5. Latin America Nasal Allergy Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.5.1. Key Highlights
      • 7.5.1.1. Brazil Nasal Allergy Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 7.5.1.2. Brazil Nasal Allergy Treatment Market Indication, Value (US$ Bn), 2018 - 2031
      • 7.5.1.3. Brazil Nasal Allergy Treatment Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 7.5.1.4. Brazil Nasal Allergy Treatment Market End User, Value (US$ Bn), 2018 - 2031
      • 7.5.1.5. Mexico Nasal Allergy Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 7.5.1.6. Mexico Nasal Allergy Treatment Market Indication, Value (US$ Bn), 2018 - 2031
      • 7.5.1.7. Mexico Nasal Allergy Treatment Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 7.5.1.8. Mexico Nasal Allergy Treatment Market End User, Value (US$ Bn), 2018 - 2031
      • 7.5.1.9. Argentina Nasal Allergy Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 7.5.1.10. Argentina Nasal Allergy Treatment Market Indication, Value (US$ Bn), 2018 - 2031
      • 7.5.1.11. Argentina Nasal Allergy Treatment Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 7.5.1.12. Argentina Nasal Allergy Treatment Market End User, Value (US$ Bn), 2018 - 2031
      • 7.5.1.13. Rest of Latin America Nasal Allergy Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 7.5.1.14. Rest of Latin America Nasal Allergy Treatment Market Indication, Value (US$ Bn), 2018 - 2031
      • 7.5.1.15. Rest of Latin America Nasal Allergy Treatment Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 7.5.1.16. Rest of Latin America Nasal Allergy Treatment Market End User, Value (US$ Bn), 2018 - 2031
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Nasal Allergy Treatment Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Nasal Allergy Treatment Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Immunotherapy
      • 8.1.1.2. Antihistamines
      • 8.1.1.3. Decongestants
      • 8.1.1.4. Corticosteroids
      • 8.1.1.5. Others
  • 8.2. Middle East & Africa Nasal Allergy Treatment Market Outlook, by Disease, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Seasonal Allergic Rhinitis
      • 8.2.1.2. Perennial Allergic Rhinitis
      • 8.2.1.3. Occupational Allergic Rhinitis
  • 8.3. Middle East & Africa Nasal Allergy Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Oral
      • 8.3.1.2. Nasal
      • 8.3.1.3. Intraocular
      • 8.3.1.4. Intravenous
  • 8.4. Middle East & Africa Nasal Allergy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. Retail Pharmacies
      • 8.4.1.2. Hospital Pharmacies
      • 8.4.1.3. E - Commerce
  • 8.5. Middle East & Africa Nasal Allergy Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.5.1. Key Highlights
      • 8.5.1.1. GCC Nasal Allergy Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 8.5.1.2. GCC Nasal Allergy Treatment Market Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.3. GCC Nasal Allergy Treatment Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 8.5.1.4. GCC Nasal Allergy Treatment Market End User, Value (US$ Bn), 2018 - 2031
      • 8.5.1.5. South Africa Nasal Allergy Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 8.5.1.6. South Africa Nasal Allergy Treatment Market Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.7. South Africa Nasal Allergy Treatment Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 8.5.1.8. South Africa Nasal Allergy Treatment Market End User, Value (US$ Bn), 2018 - 2031
      • 8.5.1.9. Egypt Nasal Allergy Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 8.5.1.10. Egypt Nasal Allergy Treatment Market Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.11. Egypt Nasal Allergy Treatment Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 8.5.1.12. Egypt Nasal Allergy Treatment Market End User, Value (US$ Bn), 2018 - 2031
      • 8.5.1.13. Nigeria Nasal Allergy Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 8.5.1.14. Nigeria Nasal Allergy Treatment Market Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.15. Nigeria Nasal Allergy Treatment Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 8.5.1.16. Nigeria Nasal Allergy Treatment Market End User, Value (US$ Bn), 2018 - 2031
      • 8.5.1.17. Rest of Middle East & Africa Nasal Allergy Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 8.5.1.18. Rest of Middle East & Africa Nasal Allergy Treatment Market Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.19. Rest of Middle East & Africa Nasal Allergy Treatment Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 8.5.1.20. Rest of Middle East & Africa Nasal Allergy Treatment Market End User, Value (US$ Bn), 2018 - 2031
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Artery Type vs Indication Heatmap
  • 9.2. Manufacturer vs Indication Heatmap
  • 9.3. Company Market Share Analysis, 2023
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Merck & Co.
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Product Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Boehringer Ingelheim
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Product Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. AstraZeneca
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Product Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. GlaxoSmithKline PLC
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Product Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. Sanofi S.A.
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Product Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. Johnson & Johnson
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Product Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. Teva Pharmaceutical Industries Ltd.
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Product Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. Alcon (Novartis AG)
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Product Portfolio
      • 9.5.8.3. Financial Overview
      • 9.5.8.4. Business Strategies and Development
    • 9.5.9. Stallergenes Greer
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Product Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development
    • 9.5.10. Allergy Therapeutics
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Product Portfolio
      • 9.5.10.3. Financial Overview
      • 9.5.10.4. Business Strategies and Development
    • 9.5.11. ALK-Abello A/S
      • 9.5.11.1. Company Overview
      • 9.5.11.2. Product Portfolio
      • 9.5.11.3. Financial Overview
      • 9.5.11.4. Business Strategies and Development
    • 9.5.12. Hanmi Pharmaceutical
      • 9.5.12.1. Company Overview
      • 9.5.12.2. Product Portfolio
      • 9.5.12.3. Financial Overview
      • 9.5.12.4. Business Strategies and Development
    • 9.5.13. Immunotek
      • 9.5.13.1. Company Overview
      • 9.5.13.2. Product Portfolio
      • 9.5.13.3. Financial Overview
      • 9.5.13.4. Business Strategies and Development
    • 9.5.14. Regeneron Pharmaceuticals
      • 9.5.14.1. Company Overview
      • 9.5.14.2. Product Portfolio
      • 9.5.14.3. Financial Overview
      • 9.5.14.4. Business Strategies and Development
    • 9.5.15. Abdi Ibrahim Pharmaceuticals
      • 9.5.15.1. Company Overview
      • 9.5.15.2. Product Portfolio
      • 9.5.15.3. Financial Overview
      • 9.5.15.4. Business Strategies and Development
    • 9.5.16. Glenmark
      • 9.5.16.1. Company Overview
      • 9.5.16.2. Product Portfolio
      • 9.5.16.3. Financial Overview
      • 9.5.16.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!